首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1935316

銀屑病治療市場：按治療方法、通路和地區分類

Psoriasis Treatment Market, By Therapy Type, By Distribution Channel, By Geography

出版日期: 2026年01月14日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026 年銀屑病治療市場價值為 342 億美元，預計到 2033 年將達到 715 億美元，2026 年至 2033 年的複合年成長率為 11.1%。

報告內容		報告詳情
基準年：	2025	2026年市場規模：	342億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
預測期（2026-2033年）複合年成長率：	11.10%	2033 年的預測值：	715億美元

隨著醫學研究人員從一般免疫抑制轉向高度標靶化的免疫通路，乾癬治療市場正在發生顯著變化，擴大了長期緩解的可能性。白細胞介素(IL) 抑制劑、TYK2 抑制劑的策略性進展以及生物相似藥的日益普及，在影響這些市場動態發揮關鍵作用。乾癬管理方案已成為包括皮膚科、風濕科和基層醫療在內的多個臨床學科的重要醫療保健工具。

生物標記數據與人工智慧驅動的治療方案相結合，提高了疾病管理的精確度和一致性。非類固醇泡沫劑和窄頻UVB照光治療等創新給藥系統，正在提升患者依從性並改善安全性。這種轉變為提供高效、療效穩定且安全性良好的生物製藥和口服小分子藥物的醫療機構創造了競爭優勢。這些突破使臨床醫生能夠提供個人化治療，旨在全面改善全球數百萬患者的皮膚狀況並提高其生活品質。

市場動態

銀屑病治療市場正經歷顯著成長，主要驅動力來自皮膚病學和免疫學領域日益成長的需求。在全球對長期改善皮膚狀況的需求不斷成長的背景下，生物製藥因其卓越的靶向性、安全性以及對中重度病例的高效性，正逐漸成為首選治療方案。製藥公司擴大採用白細胞介素類藥物來滿足嚴格的臨床標準並改善患者的生活品質，尤其是在全球醫療體係日益收緊慢性病管理和白細胞介素控制相關法規的情況下。這些變化使得患者能夠獲得針對疾病系統性根本原因而非僅針對錶面症狀的有效治療。

IL-17 和 IL-23 抑制劑在臨床應用中的日益普及，顯著推動了精準醫療的需求，並對市場產生了積極影響。現代生物製藥的天然特性，例如快速清除斑塊、持久緩解、患者依從性高以及易於自行注射等，使其成為皮膚健康領域多種應用的理想選擇。利用先進的分子定位標記，醫生可以更清楚地了解患者的免疫反應，並有效糾正導致皮膚出現紅腫搔癢斑塊的過度活躍路徑。

此外，由於零售藥局中口服小分子藥物和生物相似藥的使用日益增多，消費者對價格適中且無需注射的治療方案的需求不斷成長，推動了市場的發展。在門診，居家治療的普及和便捷的每日給藥方式的興起，也帶動了對這些藥物的需求。專科藥房服務的成長是銀屑病治療市場成長的主要驅動力，因為它提高了患者獲得改變生活的藥物的可及性。

本次調查的主要特點

本報告對銀屑病治療市場進行了詳細分析，以 2025 年為基準年，給出了預測期（2026-2033 年）的市場規模（十億美元）和復合年成長率（%）。
它還重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
該研究根據以下參數對銀屑病治療市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
本報告的研究結果將有助於負責人和經營團隊就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
這份銀屑病治療市場報告的目標受眾是該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過各種用於分析銀屑病治療市場的策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第7章競爭情勢

Glenmark Pharmaceuticals Limited
Sun Pharmaceuticals Industries Ltd.
Cipla Ltd.
Johnson &Johnson
Rowan Bioceuticals Private Limited
Stiefel Laboratories Inc.（GlaxoSmithKline plc）
Win Medicare Pvt. Ltd
Novartis AG

第8章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第9章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI99

Psoriasis Treatment Market is estimated to be valued at USD 34.2 Bn in 2026 and is expected to reach USD 71.5 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 34.2 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.10%	2033 Value Projection:	USD 71.5 Bn

The Psoriasis Treatment Market evolves significantly as medical researchers transition from general immunosuppression to highly targeted immunological pathways, broadening the possibilities for long-term remission. Strategic advancements in interleukin (IL) inhibitors, TYK2 inhibitors, and the growing availability of biosimilars play a critical role in influencing these market dynamics. Psoriasis management solutions serve as essential healthcare tools across various clinical segments, including dermatology, rheumatology, and primary care.

The integration of biomarker data and AI powered treatment planning has enhanced the precision and consistency of disease management. Innovative delivery systems such as nonsteroidal foams and narrowband UVB phototherapy have led to higher patient adherence and improved safety standards. This shift creates a competitive advantage for providers who supply high-efficacy biologics and oral small molecules with consistent performance and favorable safety profiles. These breakthroughs allow clinicians to offer personalized treatments that aim for complete skin clearance and improved quality of life for millions of patients worldwide.

Market Dynamics

The Psoriasis Treatment Market is witnessing significant momentum largely driven by escalating demand from the dermatology and immunology sectors. With the global push toward long-term skin clearance, biologic therapies are increasingly preferred for their excellent targeted action, safety profiles, and high efficacy in moderate to severe cases. Pharmaceutical companies are adopting interleukins more proactively to meet strict clinical standards and improve patient quality of life, especially as healthcare systems worldwide tighten rules on chronic disease management and inflammation control. These shifts ensure the patients receive effective care that addresses the systemic roots of the condition rather than just surface symptoms.

The increasing use of IL-17 and IL-23 inhibitors in clinical settings is significantly propelling the demand for precision medicine, thus positively influencing the market. The natural features of modern biologic tools, such as rapid plaque clearing, long-lasting remission, high patient adherence, and easy self-injection, make them an ideal choice for multiple uses in the skin health area. By using better molecular mapping markers, doctors are allowed to keep a clear view of the patient's immune response while effectively fixing the overactive pathways that cause red itchy patches.

Furthermore, the rising use of oral small molecules and biosimilars in the retail pharmacy sector is significantly influencing the growth path of the market due to the need for affordable care and injection-free options. In outpatient clinics the demand for these drugs comes from the ongoing move toward home-based treatment and convenient daily dosing. The growth of specialty pharmacy services has become a major driving force behind the growth of the psoriasis treatment market, as they offer better access to life-changing drugs.

Key Features of the Study

This report provides in-depth analysis of the Psoriasis Treatment Market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Psoriasis Treatment Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Glenmark Pharmaceuticals Limited, Sun Pharmaceuticals Industries Ltd., Cipla Ltd., Johnson & Johnson, Rowan Bioceuticals Private Limited, Stiefel Laboratories Inc. (GlaxoSmithKline plc), Win Medicare Pvt. Ltd., and Novartis AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Psoriasis Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Psoriasis Treatment Market

Market Segmentation

Therapy Type Insights (Revenue, USD Bn, 2026 - 2033)
- Topical Treatments
- Systemic Treatments
- Biologics
- Phototherapy
Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- U.K.
- Germany
- Italy
- France
- Russia
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
Key Players Insights
- Glenmark Pharmaceuticals Limited
- Sun Pharmaceuticals Industries Ltd.
- Cipla Ltd.
- Johnson & Johnson
- Rowan Bioceuticals Private Limited
- Stiefel Laboratories Inc. (GlaxoSmithKline plc)
- Win Medicare Pvt. Ltd
- Novartis AG

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Psoriasis Treatment Market, By Therapy Type
- Global Psoriasis Treatment Market, By Distribution Channel
- Global Psoriasis Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trend

4. Global Psoriasis Treatment Market, By Therapy Type, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Topical Treatments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Systemic Treatments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Phototherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

5. Global Psoriasis Treatment Market, By Distribution Channel, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

6. Global Psoriasis Treatment Market, By Region, 2020 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

7. Competitive Landscape

Glenmark Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sun Pharmaceuticals Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Rowan Bioceuticals Private Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Stiefel Laboratories Inc. (GlaxoSmithKline plc)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Win Medicare Pvt. Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies